GCP
TCRX icon

GSA Capital Partners’s TScan Therapeutics TCRX Stock Holding History

GSA Capital Partners’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$537K Buy
548,087
+169,127
+45% +$180K 0.03% 954
2026
Q1 		$383K Buy
378,960
+152,796
+68% +$163K 0.02% 1093
2025
Q4 		$226K Buy
+226,164
New +$327K 0.02% 1339
2025
Q2 		– Sell
-41,817
Closed -$58K – 2138
2025
Q1 		$58K Buy
+41,817
New +$90.5K 0.01% 1540

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

GSA Capital Partners's TCRX Position: Q2 2026 in Review

GSA Capital Partners increased its TScan Therapeutics (TCRX) stake by 45% in Q2 2026, buying an estimated $180K and bringing the position to 548,087 shares worth $537K. The position accounts for 0.03% of the portfolio, ranked #954.

GSA Capital Partners first reported a position in TCRX in Q1 2025 and has held it in 4 quarters since. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • GSA Capital Partners held 548,087 shares of TScan Therapeutics worth $537K as of Q2 2026.
  • GSA Capital Partners bought 169,127 TScan Therapeutics shares in Q2 2026, an estimated $180K.
  • TScan Therapeutics made up 0.03% of GSA Capital Partners's portfolio in Q2 2026, its #954 holding.
  • GSA Capital Partners first reported a position in TScan Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.